Point Therapeutics, Dara Biosciences set stockholder meeting dates to decide merger

By Lisa Kerner

Charlotte, N.C., Dec. 27 - Point Therapeutics, Inc. will hold a special meeting of shareholders at 10 a.m. ET on Jan. 29 in Boston to vote on the company's merger with Dara BioSciences, Inc.

Dara stockholders will vote on the merger at a special meeting on Jan. 28 at 10 a.m. ET in Raleigh, N.C.

Under the companies' Oct. 9 merger agreement, Dara will merge with DP Acquisition Corp., a newly formed subsidiary of Point, with Dara surviving as a wholly owned subsidiary of Point.

Point will change its name to Dara BioSciences, Inc. and will be based in Raleigh.

Dara is a development-stage pharmaceutical company that acquires therapeutic molecules and medical technologies.

Boston-based Point Therapeutics develops treatments for cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.